Maxcyte (MXCT) Retained Earnings (2020 - 2026)

Maxcyte (MXCT) has reported Retained Earnings for 7 consecutive years, with $434.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Retained Earnings rose 1.2% year-over-year to $434.3 million in Q2 2026; TTM through Jun 2026 was $434.3 million, a 1.2% increase from a year earlier, with the FY2025 full-year figure at $431.9 million, up 2.34% from the prior year.
• Retained Earnings was $434.3 million for Q2 2026 at Maxcyte, roughly flat from $433.0 million in the prior quarter.
• Over five years, Retained Earnings peaked at $434.3 million in Q2 2026 and troughed at $379.5 million in Q1 2022.
• A 5-year average of $410.8 million and a median of $412.8 million in 2024 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings soared 107.25% in 2022 and increased 1.2% in 2026, its largest moves.
• Over 5 years, Retained Earnings stood at $390.8 million in 2022, then increased by 4.12% to $406.9 million in 2023, then rose by 3.72% to $422.0 million in 2024, then grew by 2.34% to $431.9 million in 2025, then climbed by 0.55% to $434.3 million in 2026.
• The last three Retained Earnings figures came in at $434.3 million (Q2 2026), $433.0 million (Q1 2026), and $431.9 million (Q4 2025), per Business Quant data.